The Pharma & Biopharma Outsourcing Association’s CMO/CDMO Members and Affiliate Members are involved in every aspect of pandemic response, helping customers, governments and academic institutions develop vaccines, treatments and testing kits against COVID-19. PBOA members are also hard at work with existing projects, making sure new treatments reach patients.
PBOA MEMBER ACTIVITIES
- 4/6/21 – Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
- 3/23/21 – Jubilant HollisterStier Announces COVID-19 Vaccine Candidate Manufacturing Agreement with Novavax
- 3/17/21 – Catalent Expands Partnership with Johnson & Johnson to Significantly Increase Capacity for Sterile Manufacturing and Packaging of COVID-19 Vaccine in Italy
- 3/9/21 – Jubilant HollisterStier Signs Manufacturing Agreement with Eli Lilly for COVID-19 Therapeutic Bamlanivimab
- 3/8/21 – Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
- 2/3/21 – Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
- 1/27/21 – Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study
- 1/11/21 – Baxter Biopharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine
- 12/16/20 – Spokesman-Review – Jubilant-HollisterStier in Spokane alone in Washington in manufacturing COVID-19 vaccines
- 12/15/20 – New York Times – Critical to Vaccines, Cold Storage Is Wall Street’s Shiny New Thing (incl. PCI Pharma Services)
- 9/25/20 – GRAM Partners with Johnson & Johnson on Manufacturing in Fight Against COVID-19
- 9/24/20 – Humanigen Collaborates With Thermo Fisher To Expand Manufacturing Capacity For Lenzilumab
- 9/8/20 – INOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium
- 8/26/20 – Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody
- 8/24/20 – Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
- 8/20/20 – Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine
- 8/19/20 – Humanetics Corporation and Pharmaceutics International, Inc. (Pii) Announce Partnership in Support of BIO 300 Clinical Trials in COVID-19 Patients
- 8/6/20 – Federal Government Selects Grand River Aseptic Manufacturing to Help Combat COVID-19
- 7/16/20 – Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab
- 6/25/20 – Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
- 6/22/20 – Catalent Partners with ViralClear Pharmaceuticals on Potential Treatment for COVID-19
- 6/15/20 – Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate
- 6/10/20 – Catalent Partners with Spicona to Develop COVID-19 Vaccine Candidate Using GPEx® Cell Line Development Platform
- 5/27/20 – Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19
- 5/13/20 – Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program
- 5/7/20 – Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19
- 5/7/20 – Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program
- 5/5/20 – Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials
- 5/4/20 – Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
- 4/29/20 – Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
- 4/28/20 – From Pfizer‘s 1Q20 earnings statement: “Pfizer is taking a number of steps simultaneously to scale up manufacturing operations at risk to accelerate its ability to supply a potential novel treatment or vaccine for COVID-19. Pfizer is also committed to offering any excess manufacturing capacity and to potentially shifting production in order to support others’ efforts to manufacture any life-saving breakthroughs that may be developed to combat COVID-19.“
- 4/28/20 – Supporting Client Launches During COVID19: Sharp Packaging US Supports Launch of Two Cancer Therapies
- 4/24/20 – CMIC Group issues notice regarding the start of sales of antibody test kit for COVID‐19 research: “Novel coronavirus (SARS-CoV-2) IgG/IgM Antibody Test”
- 4/23/20 – CMIC Group supports clinical trials and manufacturing of influenza antiviral drug “Avigan® Tablet” and contributes to accelerating provision for COVID-19 patients
- 4/23/20 – Cytovance Biologics And Akshaya Bio Announce Collaboration Agreement Of Therapeutics For Treatment Of Coronavirus And Hepatitis B Virus Infections
- 4/7/20 – Sharp Clinical Supports Development of Novel COVID-19 Vaccines and Treatments
- 3/10/20 – GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(™) Therapeutic for Treatment of Coronavirus Infection
PBOA Member Resources
- Alcami – COVID-19 Updates and Resources
- Bora Corp.‘s responsibility to navigate COVID19: A message from Bora’s CEO Bobby Sheng
- Catalent Responds To The Global Outbreak of COVID-19
- Catalent COVID-19 Response
- Cytovance COVID-19 Resource
- Lubrizol Life Science Health CDMO Division – Lubrizol’s Commitment to Improving Lives During COVID-19
- raMarketing COVID-19 Toolkit
- Sharp Services – COVID-19: A catalyst for change in global clinical trials
- Skyland Analytics Offers Free Software Licenses to Support Accelerated COVID-19 Product-Process Development
